Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Thus, as with any new treatment modality, caution is required in the follow-up of patients receiving TNF blocker treatment, since new side effects and complications are continuously being reported.

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with ...

In fact, rates of adverse events such as respiratory hospitalization, death from lung disease, and all-cause mortality were numerically higher in the non-TNF inhibitor users -- hazard ratios ...

3 TNF inhibitor drug category: the global market value for TNF inhibitors was estimated to be $39.7 billion in 2024. Growing at an expected CAGR of 3.6% for the next five years, the TNF inhibitor ...

Etanercept is one of the most frequently used TNF blockers, and has been approved for use in not only moderate-to-severe plaque psoriasis but also rheumatoid arthritis, polyarticular juvenile ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...

The second aspect to be addressed is that osteoproliferation (i.e. growth of syndesmophytes) cannot be inhibited by short-term treatment with TNF blockers, especially when erosive structural ...

The first study examines TNF-a levels in patients receiving the GLP-1 agonist Wegovy ® or Ozempic ® who show signs of increased inflammation associated with sarcopenia, which is the progressive loss ...